Cargando…
Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
Dyslipidemia, highly elevated, low-density lipoprotein (LDL) cholesterol, is a major cardiovascular risk factor. Statins have been proven to effectively reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and are recommended as a first-line therapy for the primary and secondary prevent...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Society of Lipidology and Atherosclerosis
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379114/ https://www.ncbi.nlm.nih.gov/pubmed/32821708 http://dx.doi.org/10.12997/jla.2019.8.2.183 |